Crack lung – a case report
Abstract
Introduction. Crack cocaine (CC), a potent form of cocaine, is well-known for its rapid and intense effects on the central nervous system. Its detrimental impact on the respiratory system is often disregarded. This type of cocaine originates from cocaine hydrochloride, a compound extracted from the leaves of the coca plant (Erythroxylum coca). Through various pathophysiological mechanisms, its pharmacokinetics and interaction with the respiratory system contribute to acute and chronic lung damage. Case report. We present a 35-year-old male with progressive dyspnea and chronic lung damage caused by long-term abuse of CC. Morphological changes in the lungs along with abnormalities in pulmonary function tests were also observed. The patient was treated with a combination of medication therapy and enrolled in a detoxification support program. The applied therapeutic measures led to a gradual reduction in symptoms and significant improvement in pulmonary function tests. Conclusion. CC-induced lung damage represents a clinical challenge with profound implications for patient health and well-being. Substance abuse counseling, relapse prevention strategies, and social support services are key components of comprehensive treatment to support patient recovery and prevent relapse.
References
Redman M. Cocaine: What is the Crack? A Brief History of the Use of Cocaine as an Anesthetic. Anesth Pain Med 2011; (2): 95–7.
Butler AJ, Rehm J, Fischer B. Health outcomes associated with crack-cocaine use: Systematic review and meta-analyses. Drug Alcohol Depend 2017; 180: 401–16.
Roque Bravo R, Faria AC, Brito-da-Costa AM, Carmo H, Mladěnka P, Dias da Silva D, et al. On Behalf of The Oemonom Researchers. Cocaine: An Updated Overview on Chemistry, Detection, Biokinetics, and Pharmacotoxicological Aspects including Abuse Pattern. Toxins (Basel) 2022; 14(4): 278.
Dinis-Oliveira RJ. Metabolomics of cocaine: Implications in toxicity. Toxicol Mech Methods 2015; 25(6): 494–500.
Docherty JR, Alsufyani HA. Pharmacology of Drugs Used as Stimulants. J Clin Pharmacol 2021; 61 Suppl 2: S53–S69.
EMCDDA. European Drug Report 2021: Trends and Devel-opments. Luxembourg: Publications Office of the European Union; 2021. p. 60.
Drent M, Wijnen P, Bast A. Interstitial lung damage due to co-caine abuse: pathogenesis, pharmacogenomics and therapy. Curr Med Chem 2012; 19(33): 5607–11.
Underner M, Peiffer G, Perriot J, Jaafari N. Pulmonary complica-tions in cocaine users. Rev Mal Respir 2020; 37(1): 45–59. (French)
Dolapsakis C, Katsandri A. Crack lung: A case of acute pulmo-nary cocaine toxicity. Lung India 2019; 36(4): 370–1.
Wireko F, Leys L, Donaldson S, Thomas A. Crack lung with crack cocaine. Chest 2021; 160(4): A1725.
Lison D, Arietti F, Segre E, Rossi S. Crack-use-associated pneumonia: a case report. Ital J Emerg Med 2023; 12(1): 55–8.
Fischer B, Blanken P, Da Silveira D, Gallassi A, Goldner EM, Rehm J, et al. Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: a compre-hensive narrative overview of English-language studies. Int J Drug Policy 2015; 26(4): 352–63.
Minozzi S, Saulle R, Amato L, Traccis F, Agabio R. Psychosocial interventions for stimulant use disorder. Cochrane Database Syst Rev 2024; 2(2): CD011866.
Junior MSC, Bezerra AG, Curado DF, Gregório RP, Galduróz JCF. Preliminary investigation of the administration of biperi-den to reduce relapses in individuals with cocaine/crack user disorder: A randomized controlled clinical trial. Pharmacol Biochem Behav 2024; 237: 173725.